Vertex Pharmaceuticals Inc (NASDAQ:VRTX)

64.17
Data as of Apr 17
 -0.22 / -0.34%
Today’s Change
51.96
Today|||52-Week Range
89.96
-13.63%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$15.5B

Company Description

Vertex Pharmaceuticals, Inc. is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The company's research focuses on cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. Its product pipe line includes NCIVEK (telaprevir), which is marketed in the U.S. and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which it markets in the U.S., Canada and Europe for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation that is referred to as the G551D mutation. The company's other drug candidates include ivacaftor, VX-809, VX-661, VX-135, VX-222, VX-509 and VX-787. Vertex Pharmaceuticals was founded by Boger S. Joshua in 1989 and is headquartered in Cambridge, MA.

Contact Information

Vertex Pharmaceuticals, Inc.
130 Waverly Street
Cambridge Massachusetts 02139-4242
P:(617) 444-6100
Investor Relations:

Employees

Shareholders

Mutual fund holders62.42%
Other institutional33.02%
Individual stakeholders1.10%

Top Executives

Jeff M. LeidenChairman, President & Chief Executive Officer
Ian F. SmithChief Financial Officer & Executive Vice President
Peter R. MuellerChief Scientific Officer
Robert KauffmanChief Medical Officer & Senior Vice President
Kenneth L. HortonChief Legal Officer & Executive Vice President

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.